Bristol Myers Squibb said in its 2025 highlights that Growth Portfolio sales increased 17% for the 9 months ended September 30, 2025 compared with the prior-year period, and that it had 4 assets with annualized sales exceeding $1B based on 3Q 25 worldwide revenue.

1. 01

   Bristol Myers Squibb said in its 2025 highlights that Growth Portfolio sales increased 17% for the 9 months ended September 30, 2025 compared with the prior-year period, and that it had 4 assets with annualized sales exceeding $1B based on 3Q 25 worldwide revenue.

2. 02

   The company said it returned capital to shareholders through approximately $14.5B in dividends and approximately $8B in share repurchases over the past 3 years. It added that it paid dividends for 94 consecutive years, with the most recent dividend declared on December 10, 2025 and payable on February 2, 2026.

3. 03

   Bristol Myers Squibb cited 2026 NME registrational trial data including admilparant for IPF (ALOFT-IPF), arlo-cel 4L+ MM (QUINTESSENTIAL), and milvexian for AF (LIBREXIA-AF1). For LCM key data, it cited Cobenfy for AD psychosis (ADEPT-1, 2 & 4) and Sotyktu for SLE (POETYK SLE-1 & 2).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.